Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Total Valuation
BHVN has a market cap or net worth of $2.52 billion. The enterprise value is $2.31 billion.
| Market Cap | 2.52B |
| Enterprise Value | 2.31B |
Important Dates
The last earnings date was Tuesday, November 14, 2023, after market close.
| Earnings Date | Nov 14, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
BHVN has 80.08 million shares outstanding. The number of shares has increased by 73.51% in one year.
| Shares Outstanding | 80.08M |
| Shares Change (YoY) | +73.51% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 14.47% |
| Owned by Institutions (%) | 100.97% |
| Float | 62.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.68 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.00, with a Debt / Equity ratio of 0.10.
| Current Ratio | 5.00 |
| Quick Ratio | n/a |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -110.10% and return on invested capital (ROIC) is -155.75%.
| Return on Equity (ROE) | -110.10% |
| Return on Assets (ROA) | -85.60% |
| Return on Capital (ROIC) | -155.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.30M |
| Employee Count | 202 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -14.31M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +118.18% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | +118.18% |
| 50-Day Moving Average | 26.23 |
| 200-Day Moving Average | 20.03 |
| Relative Strength Index (RSI) | 62.39 |
| Average Volume (30 Days) | 1,185,044 |
Short Selling Information
The latest short interest is 6.72 million, so 8.39% of the outstanding shares have been sold short.
| Short Interest | 6.72M |
| Short Previous Month | 7.12M |
| Short % of Shares Out | 8.39% |
| Short % of Float | 10.80% |
| Short Ratio (days to cover) | 5.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -495.75M |
| Pretax Income | -478.83M |
| Net Income | -464.52M |
| EBITDA | -473.47M |
| EBIT | -478.83M |
| Earnings Per Share (EPS) | -$7.22 |
Balance Sheet
The company has $240.62 million in cash and $28.29 million in debt, giving a net cash position of $212.34 million or $2.65 per share.
| Cash & Cash Equivalents | 240.62M |
| Total Debt | 28.29M |
| Net Cash | 212.34M |
| Net Cash Per Share | $2.65 |
| Equity / Book Value | 290.01M |
| Book Value Per Share | 3.62 |
| Working Capital | 248.39M |
Cash Flow
In the last 12 months, operating cash flow was -$292.25 million and capital expenditures -$2.88 million, giving a free cash flow of -$295.13 million.
| Operating Cash Flow | -292.25M |
| Capital Expenditures | -2.88M |
| Free Cash Flow | -295.13M |
| FCF Per Share | -$4.32 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BHVN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -18.45% |
| FCF Yield | -11.72% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -73.51% |
| Shareholder Yield | -73.51% |
Analyst Forecast
The average price target for BHVN is $29.40, which is -6.49% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $29.40 |
| Price Target Difference | -6.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |